Summary of Significant Accounting Policies - Accounts receivable (Details) |
Mar. 31, 2024
USD ($)
customer
|
Dec. 31, 2023
USD ($)
|
Mar. 31, 2023
customer
|
---|---|---|---|
Accounts receivable | |||
Number of customers | customer | 2 | ||
Accounts receivable | $ 8,404,000 | $ 821,000 | |
Allowance for doubtful accounts | 0 | ||
Customer Concentration Risk | |||
Accounts receivable | |||
Accounts receivable | 8,404,000 | $ 821,000 | |
Customer Concentration Risk | Genentech, Inc. | |||
Accounts receivable | |||
Accounts receivable | $ 0 | ||
Customer Concentration Risk | Genentech and GSK Customers | |||
Accounts receivable | |||
Number of customers | customer | 2 |
X | ||||||||||
- Definition Represents the number of customers. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of allowance for credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|